PATIENT ACCESS WORLD CONGRESS 2025 EUROPE

Improving Patient Access for Better Health Outcomes and Quality of Life

London, United Kingdom

Monday 20th - Tuesday 21st October 2025

KEY INDUSTRY EXPERT SPEAKERS 2025

Emma Sutcliffe 2nd degree connection Chief Patient Officer, ISPEP
Marta Contente, Sr Director, Pipeline Head of Immunology, GHEVO, TEVA
Robert Mitchell-Thain, CEO, PBC Foundation
Carole Scrafton, Director & Co-Founder, Flutters and Strutters
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Lindsay Birrell, Co-CEO, Realise Advocacy
Katherine Taylor, Patient Advocacy Lead, Pfizer UK
Victoria Hayes, Director Public Affairs, Northern Cluster, Kyowa Kirin
GLENN DARLEY Patient Engagement Lead, EMEA Recordati Rare Disease
STEVE CLARK Founder and Patient Advocate Strive for Five
Sjors van Gijzel, Researcher, Access to Medicines Foundation
Katja Berg, Global Value and Access Strategy, BBU, AstraZeneca
Bob Stevens, Group CEO, MPS.SOCIETY
Beverly Lui, Head, Patient Advocacy and Engagement International Region, Apellis
And much much more...

JOSIE GODFREY

Director, JG Zebra Consulting, Co-Founder and CEO

Realise Advocacy

JOSIE GODFREY

Director, JG Zebra Consulting, Co-Founder and CEO

>Strategic Director, Project HERCULES >Director, JG Zebra Consulting >Former Associate Director, NICE (Highly Specialised Technologies and Topic Selection) >Former Head of Policy, NHS National Specialised Commissioning >International Policy and Patient Advocacy, Sobi

LINDSAY BIRRELL

Co- CEO, Realise Advocacy, Chair of trustees

Medics 4 Rare Diseases

LINDSAY BIRRELL

Co- CEO, Realise Advocacy, Chair of trustees

Former CEO of Metabolic Support UK >Chair of trustees at Medics 4 Rare Diseases. >Former member NHS England Metabolic Clinical Reference Group >Patient Advocacy Group experience of UK routes to access >PPV rep on NHSEi Rare disease Advisory Group

CAROLE SCRAFTON

CEO & Co-Founder Patient Advocacy Organisation

FibroFlutters

CAROLE SCRAFTON

CEO & Co-Founder Patient Advocacy Organisation

Carole is a patient with chronic and genetic rare disease, Patient Partner, Expert Patient, Patient Speaker, Author and Researcher. She is the CEO & Co-founder of FibroFlutters Patient Advocacy Organisation for chronic / rare illnesses. Helping to develop, nurture and advocate for a multidisciplinary approach to all aspects of medical healthcare so that chronic illness & rare disease patients can receive the type of care and treatments that they need. Carole utilises varying social media platforms to support people with Chronic illness & Rare Disease, #notjustpatients, and with a multi-stakeholder following. A network used for raising disease awareness and sharing as much up to date information. Carole also advocates for patientcentricity, especially patient engagement best practices and the need for patients to be included within research at early development / preclinical phases. She recognises the need to help educate patients about clinical trials and the reason why they should get involved. Recently as a Patient, and with FibroFlutters, was a team member of an initiative to create: ‘How-To guide’. How to implement Patient Engagement into Early Development and Preclinical phases with Patients Focused Medicines Development.

ROBERT MITCHELL-THAIN

CEO

PBC Foundation

ROBERT MITCHELL-THAIN

CEO

Drawn into the world of PBC with his mother's diagnosis in 1994, Robert has, in one way or another, been involved in PBC advocacy since even before the PBC Foundation was founded in 1996. An experienced and powerful patient advocate, Robert's specialist subject is listening to the patient, and using the patient experience to improve the patient experience. An international leader, presenter, innovator, academic, committee member and author on a number of topics, his driver is to ensure the patient voice, and experience, is front and centre of every potential solution to the challenges they face. An agent for change, he has led various campaigns and innovations to improve the PBC patients' quality of life on a multinational stage.

Emma Sutcliffe

Chief Patient Officer

ISPEP

Emma Sutcliffe

Chief Patient Officer

Biopharma, where she leads a dedicated team of Global Patient Directors and is responsible for continuously improving and inspiring excellence in patient engagement practices across the entire organization including a patient champion network of 180 colleagues working with almost 300 patient organizations. As a Medical Biochemist and Psychotherapist, Emma has dedicated her career to amplifying the patient voice in the research and development of medicines and creating patient solutions; accordingly, Emma is one of the most frequently published and awarded leaders in the sector.

GLENN DARLEY

Patient Engagement Lead, EMEA

Recordati Rare Disease

GLENN DARLEY

Patient Engagement Lead, EMEA

STEVE CLARK

Founder and Patient Advocate

Strive for Five

STEVE CLARK

Founder and Patient Advocate

Steve Clark was diagnosed with stage 4 colorectal cancer in 2013 and has since become an active patient advocate. He is a regular speaker for audiences of patients, healthcare professionals, researchers, and industry representatives as well as volunteering with several charities including being a Campaigns Ambassador for Cancer Research UK. Steve is a patient representative to several studies and study groups and has been co-author on a number of papers. In 2017 he set up www.StriveForFive.org, a not-for-profit organization with the mission to give hope to fellow patients with stage 4 cancer and to advocate for improved care for those with advanced cancer. He is a business and marketing consultant for the pharmaceutical industry with Redwood Brand Curators and has worked in UK and global pharma for over 35 years in business management and global marketing. Steve is a former Chairman of the Pharmaceutical Marketing Society and was awarded Healthcare Communications Advocate by Communiqué.

Marta Contente

Sr Director, Pipeline Head of Immunology, GHEVO

TEVA

Marta Contente

Sr Director, Pipeline Head of Immunology, GHEVO

Marta is currently the Immunology Pipeline Head at TEVA, where she leads the Immunology Global HEVO team. She oversees the strategic direction of the Global Value Teams and is responsible for enhancing the focus on value assessment and payer needs for pipeline assets. Before joining TEVA, Marta was a Senior Director of Global Health Economics and Outcomes Research at Bristol Myers Squibb (BMS). She led a team responsible for supporting country HTA submissions and access for Cardiology, Immunology and Neuroscience products. Her responsibilities covered all countries outside of the US. Before this role Marta worked within the BMS global HEOR team across Oncology indications and at the Portuguese affiliate across company portfolio (Virology, Metabolics, Haem and Oncology) Previously to BMS, Marta worked at GSK and Pfizer as Market Access manager (Portugal), as well as at Lundbeck in Global Pricing. Marta holds a degree in Pharmaceutical Sciences from Lisbon University, a Postgraduate Diploma in Health Economics from University of York and an Executive MBA from AESE - IESE Business School.

Victoria Hayes

Director Public Affairs, Northern Cluster

Kyowa Kirin

Victoria Hayes

Director Public Affairs, Northern Cluster

Vicky has 19 years of experience in government affairs and advocacy, with specific expertise in the pharmaceutical sector across Europe. She has led major campaigns on access to innovative treatments, service redesign and the crucial importance of the patient and public voice in the health debate. As a former Governor of the UK's largest mental health trust and today as a mental health advocate she focuses on health equity across the board. She is passionate about innovation strategies, women’s health and systems thinking.

Katherine Taylor

Patient Advocacy Lead

Pfizer UK

Katherine Taylor

Patient Advocacy Lead

Katherine is the Patient Advocacy lead for Pfizer UK, driving a patient centric strategy and culture to deliver better outcomes for patients. Katherine has had a ten-year career in Patient Advocacy, having worked in the third sector prior to joining Pfizer.

Beverly Lui

Head, Patient Advocacy and Engagement International Region

Apellis

Beverly Lui

Head, Patient Advocacy and Engagement International Region

Beverly is a pediatric pharmacist by training and has spent over 20 years working in biotechnology, holding diverse Medical Affairs roles across Europe, the United States, Asia Pacific and Emerging Markets. Her mission is to bridge the gap between medical innovation and patient accessibility, driven by a passion for developing therapies that truly resonate with patient needs and delivering outcomes that are meaningful to them. Witnessing the significant access challenges faced by innovative medicines in reaching people in need prompted her to pivot into patient advocacy. She is now dedicated to addressing these barriers across the drug development lifecycle, collaborating with patients and those who care for them, physicians, access decision-makers and industry stakeholders to ensure that transformative therapies that are developed can reach those who need them most

KATJA BERG

Innovative Value and Access Strategy

AstraZeneca

KATJA BERG

Innovative Value and Access Strategy

Katja Berg is a strategic leader in the biotech and pharmaceutical industry with 20+ years of science, management consulting, pricing and market access experience. In her global role of Innovative Value & Access Strategy within the Biopharmaceutical Business Unit at AstraZeneca, Katja is responsible for bringing novel approaches and future-looking access models for AstraZeneca’s portfolio to advance patient access and value-based healthcare. Katja spent her early years in the laboratory and Academia, mostly in Sweden, France and the US, authoring publications while nurturing her scientific curiosity and languages. She then became a senior consulting leader and Global Client Partner for Top 15 pharmaceutical companies for over 10 years at IMS Consulting [today IQVIA], leading among other things thought leadership for the practice. Transitioning from consulting to the biopharmaceutical industry, Katja led a multi-functional global team delivering above brand strategic, operational and policy-related pricing and access activities for Sanofi. During this time, she lead and coordinated Sanofi’s position on external access policy and working groups such as IFPMA and Access Accelerated, including work designing and incubating end-to-end patient access solutions in e.g. Asia and Africa. During her 3 years at AstraZeneca, Katja has delivered global pricing and access launch strategies for assets within the Cardiovascular, Renal & Metabolism (CVRM), Respiratory and Immunology (R&I) and Vaccines & Immune Therapies (V&I) Business Units, as well as acted as Head of Access Policy for the Australia & NZ team in Sydney.

BOB STEVENS

Group CEO

MPS.SOCIETY

BOB STEVENS

Group CEO

Having two sons diagnosed with a rare disease (MPSII) changes your perspective and priorities in life. Having spent over 20 years in construction, many of which were at Board level, Bob decided to pursue a career in the Charity sector. At first becoming a Trustee, then progressed to Managing Director and Group CEO of various patient organisations, supporting those living with rare diseases and complex needs. Bob wanted to bring together his family experiences of a "Rare life lived" and commercial attributes in order to improve the lives of those most marginalised in society whilst, at the same time, helping to create a more sustainable financial future for patient organisations both in the UK and globally. As well as being Group CEO of the MPS Society/Rare Disease Research Partners he is proud to serve as Vice Chair of the LSD Collaborative, Board Member of the worldwide International MPS Network, Acting Chair of the New Born Screening Collaborative and work as a patient representative for MPS in various global charitable access programs that provide a possible lifeline to treatments in selected areas of the world. These are not job roles, but a way of life!

SJORS VAN GIJZEL

Researcher

Access to Medicines Foundation

SJORS VAN GIJZEL

Researcher

Sjors van Gijzel is a Researcher at the Access to Medicine Foundation. Sjors works in the unit that looks at company pipelines and other research and development activities across the essential healthcare companies the Foundation engages with. Sjors also provides ongoing support for external stakeholder engagement with up-to-date insights on pipeline projects, priority R&D gaps, and access planning. Sjors holds a Master’s degree in Epidemiology from Utrecht University with a focus on infectious diseases and a Bachelor’s degree in Biomedical Sciences from Radboud University with a minor in global health and infectious diseases. During his studies, Sjors researched a variety of topics looking at low- and middle-income countries, including a study on an association between reduced malaria prevalence and BCG vaccination in children in sub-Saharan Africa, as well as possible differences in obstructive lung disease occurrence in people with and without HIV in South Africa.